{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:51:08Z","timestamp":1793731868468,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0334-6","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T23:24:32Z","timestamp":1442273072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A conceptual disease model for adult Pompe disease"],"prefix":"10.1186","volume":"10","author":[{"given":"Tim A.","family":"Kanters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ken","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P.M.H.","family":"Rutten-Van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Kruijshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Hakkaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,15]]},"reference":[{"key":"334_CR1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1010387522195","volume":"24","author":"B Wilcken","year":"2001","unstructured":"Wilcken B. Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? J Inherit Metab Dis. 2001;24:291\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"334_CR2","first-page":"1","volume":"52","author":"M Garau","year":"2009","unstructured":"Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: A comparative study of selected European countries. OHE Briefing. 2009;52:1\u201330.","journal-title":"OHE Briefing"},{"key":"334_CR3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.clinthera.2010.08.006","volume":"32","author":"S Vegter","year":"2010","unstructured":"Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: Focus on the underlying pharmacoeconomic evaluations. Clin Ther. 2010;32:1651\u201361.","journal-title":"Clin Ther"},{"key":"334_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA. 1995;273:59\u201365.","journal-title":"JAMA"},{"key":"334_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","volume":"86","author":"HG Hers","year":"1963","unstructured":"Hers HG. \u0391-glucosidase deficiency in generalized glycogen-storage disease (Pompe\u2019s disease). Biochem J. 1963;86:11.","journal-title":"Biochem J"},{"key":"334_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1010383421286","volume":"24","author":"JMP Hout Van den","year":"2001","unstructured":"Van den Hout JMP, Reuser AJJ, De Klerk JBC, Arts WF, Smeitink JAM, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human \u03b1-glucosidase from rabbit milk. J Inherit Metab Dis. 2001;24:266\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"334_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671\u2013676e2.","journal-title":"J Pediatr"},{"key":"334_CR8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg Van der","year":"2008","unstructured":"Van der Ploeg AT, Reuser AJJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"334_CR9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/jnnp.33.6.801","volume":"33","author":"AG Engel","year":"1970","unstructured":"Engel AG, Gomez MR. Acid maltase levels in muscle in heterozygous acid maltase deficiency and in non-weak and neuromuscular disease controls. J Neurol Neurosurg Psychiatry. 1970;33:801\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"334_CR10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0002-9343(78)90235-8","volume":"64","author":"EC Rosenow","year":"1978","unstructured":"Rosenow EC, Engel AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med. 1978;64:485\u201391.","journal-title":"Am J Med"},{"key":"334_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D G\u00fcng\u00f6r","year":"2011","unstructured":"G\u00fcng\u00f6r D, De Vries JM, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.","journal-title":"Orphanet J Rare Dis"},{"key":"334_CR12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Hout Van den","year":"2000","unstructured":"Van den Hout H, Reuser AJJ, Vulto AG, Loonen MCB, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human [alpha]-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397\u20138.","journal-title":"Lancet"},{"key":"334_CR13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg Van der","year":"2010","unstructured":"Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362:1396\u2013406.","journal-title":"N Engl J Med"},{"key":"334_CR14","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","volume":"144","author":"PS Kishnani","year":"2004","unstructured":"Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144:S35\u201343.","journal-title":"J Pediatr"},{"key":"334_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug L, D\u2019Agostino RB, Hagemans MLC, Van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: Results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.","journal-title":"Orphanet J Rare Dis"},{"key":"334_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","volume":"32","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: A report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Making. 2012;32:678\u201389.","journal-title":"Med Decis Making"},{"key":"334_CR17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10545-011-9320-x","volume":"34","author":"TA Kanters","year":"2011","unstructured":"Kanters TA, Hagemans MLC, Van der Beek NAME, Rutten FFH, Van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis. 2011;34:1045\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"334_CR18","volume-title":"Econometric analysis of cross section and panel data","author":"JM Wooldridge","year":"2002","unstructured":"Wooldridge JM. Econometric analysis of cross section and panel data. Cambridge, Massachusetts: The MIT Press; 2002."},{"key":"334_CR19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"MLC Hagemans","year":"2005","unstructured":"Hagemans MLC, Winkel LPF, Van Doorn PA, Hop WJC, Loonen MCB, Reuser AJJ, et al. Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain. 2005;128:671\u20137.","journal-title":"Brain"},{"key":"334_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","volume":"104","author":"NAME Beek Van der","year":"2011","unstructured":"Van der Beek NAME, Van Capelle CI, Van der Velden-Van Etten KI, Hop WCJ, Van den Berg B, Reuser AJJ, et al. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab. 2011;104:129\u201336.","journal-title":"Mol Genet Metab"},{"key":"334_CR21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","volume":"38","author":"JHJ Wokke","year":"2008","unstructured":"Wokke JHJ, Escolar DM, Pestronk A, Jaffe KM, Carter GT, Van den Berg LH, et al. Clinical features of late\u2010onset Pompe disease: A prospective cohort study. Muscle Nerve. 2008;38:1236\u201345.","journal-title":"Muscle Nerve"},{"key":"334_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM Vries De","year":"2012","unstructured":"De Vries JM, Van der Beek NAME, Hop WCJ, Karstens FPJ, Wokke JH, De Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study. Orphanet J Rare Dis. 2012;7:73.","journal-title":"Orphanet J Rare Dis"},{"key":"334_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl. 1993;16:5\u201340.","journal-title":"Eur Respir J Suppl"},{"key":"334_CR24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00415-006-0434-2","volume":"254","author":"MLC Hagemans","year":"2007","unstructured":"Hagemans MLC, Van Schie SPM, Janssens ACJW, Van Doorn PA, Reuser AJJ, Van der Ploeg AT. Fatigue: An important feature of late-onset Ppompe disease. J Neurol. 2007;254:941\u20135.","journal-title":"J Neurol"},{"key":"334_CR25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00018-009-0184-2","volume":"67","author":"JM Vries De","year":"2010","unstructured":"De Vries JM, Hagemans MLC, Bussmann JBJ, Van der Ploeg AT, van Doorn PA. Fatigue in neuromuscular disorders: Focus on Guillain\u2013Barr\u00e9 syndrome and Pompe disease. Cell Mol Life Sci. 2010;67:701\u201313.","journal-title":"Cell Mol Life Sci"},{"key":"334_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rmed.2008.12.009","volume":"103","author":"U Mellies","year":"2009","unstructured":"Mellies U, Lofaso F. Pompe disease: A neuromuscular disease with respiratory muscle involvement. Respir Med. 2009;103:477\u201384.","journal-title":"Respir Med"},{"key":"334_CR27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121\u20133.","journal-title":"Arch Neurol"},{"key":"334_CR28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.10045","volume":"25","author":"ISJ Merkies","year":"2002","unstructured":"Merkies ISJ, Schmitz PIM, Van der Mech\u00e9 FGA, Samijn J, Van Doorn PA. Psychometric evaluation of a new handicap scale in immune\u2010mediated polyneuropathies. Muscle Nerve. 2002;25:370\u20137.","journal-title":"Muscle Nerve"},{"key":"334_CR29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nmd.2007.03.006","volume":"17","author":"MLC Hagemans","year":"2007","unstructured":"Hagemans MLC, Laforet P, Hop WJC, Merkies ISJ, Van Doorn PA, Reuser AJJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam handicap scale. Neuromuscular Disord. 2007;17:537\u201343.","journal-title":"Neuromuscular Disord"},{"key":"334_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EQ Group","year":"1990","unstructured":"Group EQ. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"334_CR31","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","volume":"63","author":"MLC Hagemans","year":"2004","unstructured":"Hagemans MLC, Janssens A, Winkel LPF, Sieradzan KA, Reuser AJJ, Van Doorn PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology. 2004;63:1688\u201392.","journal-title":"Neurology"},{"key":"334_CR32","volume-title":"SF-36 physical & mental health summary scales: A manual for users of version 1","author":"JE Ware","year":"2001","unstructured":"Ware JE, Kosinski M. SF-36 physical & mental health summary scales: A manual for users of version 1. Lincoln, RI: QualityMetric Incorporated; 2001."},{"key":"334_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"334_CR34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch tariff: Results and arguments for an effective design for national EQ\u20105D valuation studies. Health Econ. 2006;15:1121\u201332.","journal-title":"Health Econ"},{"key":"334_CR35","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"MLC Hagemans","year":"2005","unstructured":"Hagemans MLC, Winkel LPF, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64:2139\u201341.","journal-title":"Neurology"},{"key":"334_CR36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","volume":"7","author":"A Herzog","year":"2012","unstructured":"Herzog A, Hartung R, Reuser AJJ, Hermanns P, Runz H, Karabul N, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7:35.","journal-title":"Orphanet J Rare Dis"},{"key":"334_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","volume":"19","author":"NAME Beek Van der","year":"2009","unstructured":"Van der Beek NAME, Hagemans MLC, Reuser AJJ, Hop WCJ, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscular Disord. 2009;19:113\u20137.","journal-title":"Neuromuscular Disord"},{"key":"334_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","volume":"7","author":"NAME Beek Van der","year":"2012","unstructured":"Van der Beek NAME, De Vries JM, Hagemans MLC, Hop WCJ, Kroos MA, Wokke JHJ, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: A nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.","journal-title":"Orphanet J Rare Dis"},{"key":"334_CR39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/qjmed\/hci128","volume":"98","author":"DA Hughes","year":"2005","unstructured":"Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM. 2005;98:829\u201336.","journal-title":"QJM"},{"key":"334_CR40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","volume":"109","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, De Vries JM, Brusse E, Kruijshaar ME, Hop WCJ, Murawska M, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109:174\u20138.","journal-title":"Mol Genet Metab"},{"key":"334_CR41","first-page":"111","volume-title":"Survival, quality of life and effects of enzyme replacement therapy in adults with Pompe disease","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SCA, et al. Quality of life and participation in the daily life activities of adults with Pompe disease receiving enzyme replacement therapy: 10\u00a0years of international follow-up. In: G\u00fcng\u00f6r D, editor. Survival, quality of life and effects of enzyme replacement therapy in adults with Pompe disease. Enschede: Ipskamp Drukkers; 2013. p. 111\u201323."},{"key":"334_CR42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review. J Neurol. 2013;260:951\u20139.","journal-title":"J Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0334-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:33:14Z","timestamp":1498231994000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/10\/1\/112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0334-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,15]]},"article-number":"112"}}